Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the SINERGY trial, a Phase 2 study in recurrent or metastatic head and neck squamous ...
US-based clinical genetic testing company Natera said that its Signatera test will be utilised in the newly activated ARCHER trial, a Phase III study sponsored by NRG Oncology. The trial focuses on ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the Company’s first commercial coverage policies for its molecular residual ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the submission of its premarket approval (PMA) to the U.S. Food and Drug Administration (FDA) for ...
AUSTIN, Texas, May 26, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new clinical data on its personalized and ...
Clinical management was altered in 100% of patients with a Signatera positive result Worldwide, lung cancer is the second most commonly diagnosed cancer. In the U.S., NSCLC accounts for 81% of all ...
Largest real-world dataset of personalized circulating tumor DNA (ctDNA) across lymphoma subtypes showed Signatera was prognostic of outcomes and outperformed imaging in detecting recurrence Natera, ...
Natera, Inc. is a diagnostic company focusing on cfDNA tests in women's health, organ health, and oncology. Natera's MRD test, Signatera, demonstrated strong growth, with a 64% increase in processed ...
AUSTIN, Texas, May 31, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular ...
Natera Inc. (NASDAQ:NTRA) is one of the best growth stocks to buy now. On September 30, Natera announced the publication of a validation study for its personalized molecular residual disease test, ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Molecular Oncology comparing the performance of mean ...
Largest ever ctDNA study in testicular cancer shows Signatera significantly outperformed standard of care tumor markers Testicular cancer represents approximately 95% of all GCTs 1 and is the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results